Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.

Publication Type:

Journal Article


PloS one, Volume 10, Issue 3, p.e0120561 (2015)


Biologics Production Core Facility, Comparative Medicine Core Facility, Flow Cytometry Core Facility, Immune Monitoring Core Facility, Proteomics Core Facility, Scientific Imaging Core Facility, Specialized Pathology Core Facility, Specimen Processing Core Facility


Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of radiophysical features. These differences may have important consequences for the absorbed dose to tumors and normal organs. Whereas 90Y has been successfully applied in a number of preclinical and clinical radioimmunotherapy settings, there have been few published pretargeting studies with 177Lu. We therefore compared the therapeutic potential of targeting either 90Y or 177Lu to human B-cell lymphoma xenografts in mice.